Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020065249 - THERAPEUTIC & COSMETIC USES OF BOTULINUM NEUROTOXIN SEROTYPE E

Publication Number WO/2020/065249
Publication Date 02.04.2020
International Application No. PCT/GB2019/051902
International Filing Date 04.07.2019
IPC
A61K 8/64 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
64Proteins; Peptides; Derivatives or degradation products thereof
A61Q 19/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
19Preparations for care of the skin
08Anti-ageing preparations
C07K 14/33 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
33from Clostridium (G)
A61K 38/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
A61P 17/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
CPC
A61K 38/4893
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
4886Metalloendopeptidases (3.4.24), e.g. collagenase
4893Botulinum neurotoxin (3.4.24.69)
A61K 8/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
64Proteins; Peptides; Derivatives or degradation products thereof
A61P 17/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61Q 19/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
19Preparations for care of the skin
08Anti-ageing preparations
C07K 14/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
33from Clostridium (G)
Applicants
  • IPSEN BIOPHARM LIMITED [GB]/[GB]
Inventors
  • PONS, Laurent
Agents
  • MACLEAN, Martin Robert
Priority Data
1815844.428.09.2018GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC & COSMETIC USES OF BOTULINUM NEUROTOXIN SEROTYPE E
(FR) UTILISATIONS THÉRAPEUTIQUES ET COSMÉTIQUES DU SÉROTYPE E DE LA NEUROTOXINE BOTULIQUE
Abstract
(EN)
The present invention is directed to a botulinum neurotoxin serotype E (BoNT/E) for use in treating a disorder, wherein the BoNT/E is administered to a human subject, and provides a maximum inhibition of neurotransmitter secretion from a target cell or tissue in ≤13 days after administration; and reduces to >25% inhibition of neurotransmitter secretion from the target cell or tissue at day 14 after administration.
(FR)
La présente invention concerne un sérotype E de neurotoxine botulique (BoNT/E) destiné à être utilisé dans le traitement d'un trouble, le BoNT/E étant administré à un sujet humain, et fournit une inhibition maximale de la sécrétion de neurotransmetteurs à partir d'une cellule ou d'un tissu cible en ≤ 13 jours après l'administration ; et réduit à > 25 % l'inhibition de la sécrétion de neurotransmetteurs à partir de la cellule ou du tissu cible au jour 14 après l'administration.
Latest bibliographic data on file with the International Bureau